Biological Dynamics Expands Adoption of ExoVerita™ Pro Under Early Access Program

03 April 2024 | Wednesday | News

Biological Dynamics, Inc., a leading innovator in exosome technology, has announced the inclusion of Hoag in its growing list of customers adopting the ExoVerita Pro instrument. This cutting-edge, automated exosomal enrichment platform is poised to revolutionize exosome-based research, empowering scientists to expedite disease detection, assess therapeutic responses, and more effectively study human health and disease.
Image Source | Public Domain

Image Source | Public Domain

“Research has shown that exosomes carry important information about human health, but studying them has proven challenging,” remarked Paul R. Billings, MD, Ph.D., CEO, and Chairman of Biological Dynamics. “Providing scientists with a more reliable, rapid, and easy-to-use option for capturing exosomes is paving the way for the era of exosomes and extracellular vesicle (EV) research, allowing researchers and translational scientists in academia and industry to develop solutions to help patients live longer and healthier lives.”

Exosomes, abundant in the human body and detectable in various biological fluids, hold crucial insights into cellular communication and disease processes. However, traditional exosome isolation methods, such as ultracentrifugation and column purification, present challenges in terms of yield, purity, and efficiency. The ExoVerita platform addresses these limitations with its automated workflow, delivering samples with high yield, purity, and reproducibility. Leveraging AC Electrokinetics (ACE) technology, this innovative platform efficiently detects and recovers exosomes from biofluids like whole blood, plasma, and serum.

“Hoag’s reputation as a national center of excellence in research has been achieved by hiring the best and brightest researchers and providing them access to innovative and beneficial technologies such as Biological Dynamics’ ExoVerita Pro,” commented Michael J. Demeure, MD, Program Director of Precision Medicine and Otis Healy Family Endowed Chair in Applied Genomics at Hoag. “The opportunity to be one of the first users of ExoVerita Pro underscores our commitment to furthering clinical understanding of cancer and other diseases by employing the latest technologies to accelerate biomarker discovery.”

Following exosome enrichment with ExoVerita Pro, researchers can utilize the collected material for various experiments, including DNA amplification and sequencing, RNA analysis, and measurement of exosome protein concentration. This wealth of information holds the potential to advance drug development, facilitate disease diagnosis and prognosis, and drive numerous other applications in biomedical research.

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close